Reuters logo
BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients
June 8, 2017 / 1:57 PM / 3 months ago

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

June 8 (Reuters) - Alkermes PLC:

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

* All participants in double-blind portion of study will be eligible to continue in open-label safety study of ALKS 3831 for additional 24 months Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below